Folia Neuropathologica
eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2025
vol. 63
 
Share:
Send email
Share:
Review paper

The role of TGFb/SMAD signaling in glioblastoma

Gulnara Kapanova
1, 2
,
Aigul Tulebayeva
3, 4
,
Aigul Bazarbayeva
3, 4
,
Assiya Turgambayeva
5
,
Aida Akhenbekova
4
,
Akmaral Abdykulova
6
,
Almat Kodasbayev
7
,
Aima Adylova
8

  1. Al-Farabi Kazakh National University, Almaty, Kazakhstan
  2. Scientific Center of Anti-infectious Drugs, Almaty, Kazakhstan
  3. Scientific Center of Pediatrics and Pediatric Surgery, Almaty, Kazakhstan
  4. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  5. Department Public Health and Management, NJSC, Astana Medical University, Astana, Kazakhstan
  6. Department of General Medical Practice No. 1, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
  7. Department of Cardiovascular Surgery, Asfendiyarov Kazakh National Medical University KazNMU, Almaty, Kazakhstan
  8. Guangdong Key Laboratory for Genome Stability and Disease Prevention and Carson International Cancer Center, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Guangdong, Shenzhen, China
Folia Neuropathol 2025; 63 (1): 1-10
DOI: https://doi.org/10.5114/fn.2025.149662
Online publish date: 2025/04/17
Article file
- The role (2).pdf  [0.18 MB]
Get citation
 
PlumX metrics:
 
1. Adylova A, Mukhanbetzhanovna AA, Attar R, Yulaevna IM, Farooqi AA. Regulation of TGFb/SMAD signaling by long non-coding RNAs in different cancers: Dark Knight in the Castle of molecular oncology. Noncoding RNA Res 2021; 6: 23-28.
2. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 2017; 35: 180-188.
3. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
4. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH; Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13: 132-142.
5. Bos EM, Binda E, Verploegh ISC, Wembacher E, Hoefnagel D, Balvers RK, Korporaal AL, Conidi A, Warnert EAH, Trivieri N, Visioli A, Zaccarini P, Caiola L, van Wijck R, van der Spek P, Huylebroeck D, Leenstra S, Lamfers MLM, Ram Z, Westphal M, Noske D, Legnani F, DiMeco F, Vescovi AL, Dirven CMF. Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial. Mol Cancer 2023; 22: 129.
6. Cabili MN, Dunagin MC, McClanahan PD, Biaesch A, Padovan-Merhar O, Regev A, Rinn JL, Raj A. Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution. Genome Biol 2015; 16: 20.
7. Cao Y, Zhang L. A Smurf1 tale: function and regulation of an ubiquitin ligase in multiple cellular networks. Cell Mol Life Sci 2013; 70: 2305-2317.
8. Chang H, Zhang J, Miao Z, Ding Y, Xu X, Zhao X, Xu P, Wang Q, Lin Y. Suppression of the Smurf1 expression inhibits tumor progression in gliomas. Cell Mol Neurobiol 2018; 38: 421-430.
9. Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M. Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res 2001; 61: 3949-3954.
10. Chen Y, Xu X, Ding K, Tang T, Cai F, Zhang H, Chen Z, Qi Y, Fu Z, Zhu G, Dou Z, Xu J, Chen G, Wu Q, Ji J, Zhang J. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO. J Exp Clin Cancer Res 2024; 43: 39.
11. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; Cancer Genome Atlas Research Network, Sood AK, Gunaratne PH, Sumazin P. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep 2018; 23: 297-312.e12.
12. Cosset EC, Godet J, Entz-Werlé N, Guérin E, Guenot D, Froelich S, Bonnet D, Pinel S, Plenat F, Chastagner P, Dontenwill M, Martin S. Involvement of the TGFb pathway in the regulation of a5 b1 integrins by caveolin-1 in human glioblastoma. Int J Cancer 2012; 131: 601-611.
13. Cui X, Huo D, Wang Q, Wang Y, Liu X, Zhao K, You Y, Zhang J, Kang C. RUNX1/NPM1/H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma. Cell Death Dis 2024; 15: 98.
14. Dikic I, Schulman BA. An expanded lexicon for the ubiquitin code. Nat Rev Mol Cell Biol 2023; 24: 273-287.
15. Dong L, Li Y, Liu L, Meng X, Li S, Han D, Xiao Z, Xia Q. Smurf1 suppression enhances temozolomide chemosensitivity in glioblastoma by facilitating PTEN nuclear translocation. Cells 2022; 11: 3302.
16. Dong L, Xu M, Li Y, Xu W, Wu C, Zheng H, Xiao Z, Sun G, Ding L, Li X, Li W, Zhou L, Xia Q. SMURF1 attenuates endoplasmic reticulum stress by promoting the degradation of KEAP1 to activate NRF2 antioxidant pathway. Cell Death Dis 2023; 14: 361.
17. Duggal R, Geissinger U, Zhang Q, Aguilar J, Chen NG, Binda E, Vescovi AL, Szalay AA. Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival. J Transl Med 2013; 11: 155.
18. Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes TGF-b receptor I and promotes oncogenesis through the activation of TGF-b signaling in glioblastoma. Nat Med 2012; 18: 429-435.
19. Eldridge AG, O’Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 2010; 17: 4-13.
20. Farooqi AA, Attar R, Qureshi MZ, Fayyaz S, Sohail MI, Sabitaliyevich UY, Nurmurzayevich SB, Yelekenova A, Yaylim I, Alaaeddine N. Interplay of long non-coding RNAs and TGF/SMAD signaling in different cancers. Cell Mol Biol (Noisy-le-grand) 2018; 64: 1-6.
21. Farooqi AA, Attar R. Role of platelet-derived growth factor-mediated signaling in carcinogenesis and metastasis. Cell Mol Biol (Noisy-le-grand) 2023; 69: 300-302.
22. Farooqi AA, Kapanova G, Kussainov AZ, Datkhayeva Z, Raganina K, Sadykov BN. Regulation of RASSF by non-coding RNAs in different cancers: RASSFs as masterminds of their own destiny as tumor suppressors and oncogenes. Noncoding RNA Res 2022; 7: 123-131.
23. Farooqi AA, Naureen H, Attar R. Regulation of cell signaling pathways by circular RNAs and microRNAs in different cancers: Spotlight on Wnt/b-catenin, JAK/STAT, TGF/SMAD, SHH/GLI, NOTCH and Hippo pathways. Semin Cell Dev Biol 2022; 124: 72-81.
24. Farooqi AA, Pinheiro M, Granja A, Farabegoli F, Reis S, Attar R, Sabitaliyevich UY, Xu B, Ahmad A. EGCG mediated targeting of deregulated signaling pathways and non-coding RNAs in different cancers: Focus on JAK/STAT, Wnt/b-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways. Cancers (Basel) 2020; 12: 951.
25. Farooqi AA, Rakhmetova V, Kapanova G, Tanbayeva G, Mussakhanova A, Abdykulova A, Ryskulova AG. Role of ubiquitination and epigenetics in the regulation of AhR signaling in carcinogenesis and metastasis: “Albatross around the Neck” or “Blessing in Disguise”. Cells 2023; 12: 2382.
26. Farooqi AA, Waseem MS, Riaz AM, Bhatti S. SMURF and NEDD4: sharp shooters monitor the gate keepers and ion traffic controllers of lead astray cell. J Membr Biol 2011; 244: 1-8.
27. Fayyaz S, Javed Z, Attar R, Farooqi AA, Yaylim I, Ahmad A. MicroRNA regulation of TRAIL mediated signaling in different cancers: Control of micro steering wheels during the journey from bench-top to the bedside. Semin Cancer Biol 2019; 58: 56-64.
28. Feng J, Ren X, Fu H, Li D, Chen X, Zu X, Liu Q, Wu M. LRRC4 mediates the formation of circular RNA CD44 to inhibit GBM cell proliferation. Mol Ther Nucleic Acids 2021; 26: 473-487.
29. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-227.
30. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495: 384-388.
31. Hiraiwa M, Fukasawa K, Iezaki T, Sabit H, Horie T, Tokumura K, Iwahashi S, Murata M, Kobayashi M, Suzuki A, Park G, Kaneda K, Todo T, Hirao A, Nakada M, Hinoi E. SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-b receptor stability. Commun Biol 2022; 5: 22.
32. Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O’Neill V, Beg MS. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 2020; 122: 1630-1637.
33. Hwang L, Ng K, Wang W, Trieu V. Treatment with trabedersen, an anti-TGF-b2 antisense, primed tumors to subsequent chemotherapies. Cancer Res 2016; 76: 3742.
34. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208.
35. Jin X, Nie E, Zhou X, Zeng A, Yu T, Zhi T, Jiang K, Wang Y, Zhang J, You Y. Fstl1 promotes glioma growth through the BMP4/Smad1/5/8 signaling pathway. Cell Physiol Biochem 2017; 44: 1616-1628.
36. Johansson E, Zhai Q, Zeng ZJ, Yoshida T, Funa K. Nuclear receptor TLX inhibits TGF-b signaling in glioblastoma. Exp Cell Res 2016; 343: 118-125.
37. Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R, Frank W. Transcriptional control of gene expression by microRNAs. Cell 2010; 140: 111-122.
38. Li H, Li J, Chen L, Qi S, Yu S, Weng Z, Hu Z, Zhou Q, Xin Z, Shi L, Ma L, Huang A, Lu Y. HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma. Clin Cancer Res 2019; 25: 3602-3616.
39. Li J, Zhang B, Feng Z, An D, Zhou Z, Wan C, Hu Y, Sun Y, Wang Y, Liu X, Wei W, Yang X, Meng J, Che M, Sheng Y, Wu B, Wen L, Huang F, Li Y, Yang K. Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis. J Exp Clin Cancer Res 2024; 43: 28.
40. Li Y, Wang H, Sun B, Su G, Cang Y, Zhao L, Zhao S, Li Y, Mao B, Ma P. Smurf1 and Smurf2 mediated polyubiquitination and degradation of RNF220 suppresses Shh-group medulloblastoma. Cell Death Dis 2023; 14: 494.
41. Liu S, Yin F, Fan W, Wang S, Guo XR, Zhang JN, Tian ZM, Fan M. Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1. J Exp Clin Cancer Res 2012; 31: 52.
42. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci U S A 2007; 104: 9667-9672.
43. Massagué J. TGFbeta in cancer. Cell 2008; 134: 215-230.
44. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024.
45. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495: 333-338.
46. Mondal B, Patil V, Shwetha SD, Sravani K, Hegde AS, Arivazhagan A, Santosh V, Kanduri M, Somasundaram K. Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration. Oncogene 2017; 36: 71-83.
47. Nie J, Xie P, Liu L, Xing G, Chang Z, Yin Y, Tian C, He F, Zhang L. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2. J Biol Chem 2010; 285: 22818-22830.
48. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
49. Qureshi MZ, Jabeen S, Butt G, Aslam A, Naqvi SK, Attar R, Tabassum S, Nasir M, Farooqi AA. Tudor tells about new twists in the story tale of SMURFs. Cell Mol Biol (Noisy-le-grand) 2016; 62: 38-43.
50. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009; 10: 398-409.
51. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 2012; 7: e30733.
52. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007; 8: 970-982.
53. Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M. Biological role and therapeutic targeting of TGF-b3 in glioblastoma. Mol Cancer Ther 2017; 16: 1177-1186.
54. Shree B, Tripathi S, Sharma V. Transforming growth factor-beta-regulated LncRNA-MUF promotes invasion by modulating the miR-34a Snail1 axis in glioblastoma multiforme. Front Oncol 2022; 11: 788755.
55. Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, Lisitsyna AA, Chubarev VN, Tarasov VV, Schiöth HB. Brain cancer drug discovery: clinical trials, drug classes, targets, and combinatorial therapies. Pharmacol Rev 2021; 73: 1-32.
56. Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer 2020; 19: 146.
57. Swatek KN, Usher JL, Kueck AF, Gladkova C, Mevissen TET, Pruneda JN, Skern T, Komander D. Insights into ubiquitin chain architecture using Ub-clipping. Nature 2019; 572: 533-537.
58. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020; 70: 299-312.
59. Tsai JM, Nowak RP, Ebert BL, Fischer ES. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol 2024; 25: 740-757.
60. Tu Y, Xu L, Xu J, Bao Z, Tian W, Ye Y, Sun G, Miao Z, Chao H, You Y, Liu N, Ji J. Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-b signaling. Oncogene 2022; 41: 2597-2608.
61. Turgambayeva A, Duisekova S, Tashenova G, Tulebayeva A, Kapanova G, Akhenbekova A, Farooqi AA. Role of TRP channels in carcinogenesis and metastasis: Pathophysiology and regulation by non-coding RNAs. Noncoding RNA Res 2023; 9: 359-366.
62. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
63. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257-2261.
64. Wang L, Lang B, Zhou Y, Ma J, Hu K. Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-b/SMAD signaling pathway. Cell Cycle 2021; 20: 1935-1952.
65. Wang W, Li Y, Tang L, Shi Y, Li W, Zou L, Zhang L, Cheng Y, Yuan Z, Zhu F, Duan Q. Cross-talk between BCKDK-mediated phosphorylation and STUB1-dependent ubiquitination degradation of BCAT1 promotes GBM progression. Cancer Lett 2024; 591: 216849.
66. Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol 2011; 12: 605-620.
67. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005; 6: 599-609.
68. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-347.
69. Xia Q, Li W, Ali S, Xu M, Li Y, Li S, Meng X, Liu L, Dong L. Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1. iScience 2021; 24: 103528.
70. Xia Q, Li Y, Han D, Dong L. SMURF1, a promoter of tumor cell progression? Cancer Gene Ther 2021; 28: 551-565.
71. Xia Q, Zhang H, Zhang P, Li Y, Xu M, Li X, Li X, Dong L. Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation. Oncogene 2020; 39: 5902-5915.
72. Yap T, Araujo D, Wood D, Denis JF, Gruosso T, Tremblay G, Connor-McCourt M, Ghosh R, Sinclair S, Nadler P, Siu L, Lakhani N. AVID200, first-in-class TGF-b1 and b3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients.
73. J Immunother Cancer 2020; 8: A6-A7.
74. Yap TA, Lakhani NJ, Araujo DV, Rodon AJ, Chandana SR, Sharma M, et al. AVID200, first-in-class TGF-b 1 and 3 selective and potent inhibitor: safety and biomarker results of a phase I
75. monotherapy dose-escalation study in patients with advanced solid tumors. J Clin Oncol 2020; 38: 3587-3587.
76. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE. Blockade of TGF-b signaling by the TGFbR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011; 71: 7155-7167.
77. Zhao K, Cui X, Wang Q, Fang C, Tan Y, Wang Y, Yi K, Yang C, You H, Shang R, Wang J, Kang C. RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFb pathway-dependent manner. Cell Death Dis 2019; 10: 877.
Copyright: © 2025 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.